Literature DB >> 20601296

Altered bone matrix mineralization in a patient with Rett syndrome.

Jochen G Hofstaetter1, Katharina M Roetzer, Petra Krepler, Kamilla Nawrot-Wawrzyniak, Thomas Schwarzbraun, Klaus Klaushofer, Paul Roschger.   

Abstract

Rett syndrome (RTT) is a common X-linked neurodevelopmental disorder caused by mutations in the coding region of methyl-CpG-binding 2 (MECP2) gene. Patients with RTT have a low bone mineral density and increased risk of fracture. However, very little is known if bone matrix mineralization is altered in RTT. A 17-year-old girl with a classical form of RTT with a heterozygous nonsense mutation in exon 3 in the MECP2-gene was treated in our hospital. Her femoral neck BMD is 43.3% below the 3rd percentile when compared to age and sex-matched controls. She underwent surgery for correction of her scoliosis, which provided a unique opportunity to obtain bone tissue to study bone matrix mineralization (Bone Mineralization Density Distribution-BMDD) using quantitative backscattered electron imaging (qBEI) and histomorphometry. BMDD outcomes were compared to recently published normative reference data for young individuals. qBEI analysis showed a significant shift to lower matrix mineralization despite histomorphometric indices indicate a low bone turnover. There was a reduction in CaMean (-7.92%) and CaPeak (-3.97%), which describe the degree of mineralization. Furthermore the fraction of low mineralized matrix (CaLow: +261.84%) was dramatically increased, which was accompanied with an increase in the heterogeneity of mineralization (CaWidth: +86.34%). Our findings show a significantly altered bone matrix mineralization of a typical patient with RTT. This may partly explain the low bone density seen in these patients. These results also warrant further studies on the molecular role of MECP2 in bone matrix mineralization. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601296     DOI: 10.1016/j.bone.2010.06.005

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Bone mineralization is elevated and less heterogeneous in adults with type 2 diabetes and osteoarthritis compared to controls with osteoarthritis alone.

Authors:  J M Pritchard; A Papaioannou; C Tomowich; L M Giangregorio; S A Atkinson; K A Beattie; J D Adachi; J DeBeer; M Winemaker; V Avram; H P Schwarcz
Journal:  Bone       Date:  2013-01-26       Impact factor: 4.398

2.  Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome.

Authors:  Saurabh K Garg; Daniel T Lioy; Hélène Cheval; James C McGann; John M Bissonnette; Matthew J Murtha; Kevin D Foust; Brian K Kaspar; Adrian Bird; Gail Mandel
Journal:  J Neurosci       Date:  2013-08-21       Impact factor: 6.167

Review 3.  The role of microglia in brain maintenance: implications for Rett syndrome.

Authors:  Noël C Derecki; James C Cronk; Jonathan Kipnis
Journal:  Trends Immunol       Date:  2012-10-31       Impact factor: 16.687

4.  Teriparatide in the treatment of recurrent fractures in a Rett patient.

Authors:  Carla Caffarelli; Jussef Hayek; Ranuccio Nuti; Stefano Gonnelli
Journal:  Clin Cases Miner Bone Metab       Date:  2015-12-29

5.  Quantification of functional abilities in Rett syndrome: a comparison between stages III and IV.

Authors:  Carlos Bm Monteiro; Geert Jp Savelsbergh; Ana Rp Smorenburg; Zodja Graciani; Camila Torriani-Pasin; Luiz Carlos de Abreu; Vitor E Valenti; Fernando Kok
Journal:  Neuropsychiatr Dis Treat       Date:  2014-07-03       Impact factor: 2.570

6.  Biomechanical properties of bone in a mouse model of Rett syndrome.

Authors:  Bushra Kamal; David Russell; Anthony Payne; Diogo Constante; K Elizabeth Tanner; Hanna Isaksson; Neashan Mathavan; Stuart R Cobb
Journal:  Bone       Date:  2014-10-24       Impact factor: 4.398

7.  Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with bone disease severity in Rett syndrome.

Authors:  Carla Caffarelli; Stefano Gonnelli; Maria Dea Tomai Pitinca; Silvia Camarri; Antonella Al Refaie; Joussef Hayek; Ranuccio Nuti
Journal:  BMC Med Genet       Date:  2020-01-31       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.